Immunomodulators

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9944678
SERIAL NO

14971352

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • BRISTOL-MYERS SQUIBB COMPANY

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Allen, Martin Patrick Flemington, US 19 210
Gillis, Eric P Cheshire, US 56 287
Miller, Michael Matthew Lambertville, US 10 157
Mull, Eric Guilford, US 30 300
Scola, Paul Michael Glastonbury, US 101 2037
Sun, Li-Qiang Glastonbury, US 57 905
Zhao, Qian Wallingford, US 225 1487

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 17, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 17, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00